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        To my parents with all my love 
  
        I close my eyes 
        And I see you everywhere 
        I step outside 
        It’s like I’m breathing you in the 
        air 
        I can feel you’re there 
        (A. & M. Bocelli) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
INDEX 
 
Chapter I 
Systemic sclerosis 
1.1 Definition          page 4 
1.2 Classification         page 4 
1.3 Epidemiology          page 5 
1.4 The most serious clinical manifestations     page 5 
1.5 Treatment outline        page 9 
 
Chapter II 
Evaluation of skin damage by modified Rodnan skin score and skin high 
frequency ultrasound 
      
2.1 Introduction         page 11 
2.2 The modified Rodnan skin score       page 11 
2.3 Skin high frequency ultrasound       page 12 
2.4 The modified Rodnan skin score vs skin high frequency ultrasound page 13 
 
Chapter III 
The fibrocytes in systemic sclerosis 
 
3.1 The role of circulating fibrocytes in systemic sclerosis   page 15 
 
Chapter IV 
Experimental Section  
Correlations between mRSS and US and circulating fibrocyte percentage and 
gene expression in limited coutaneous scleroderma patients  
 
4.1 Introduction          page 17 
4.2 Materials and methods        page 18 
4.3 Results           page 21 
4.4 Discussion          page 22 
4.5 Conclusion         page 25 
 
 
 
References            page 26 
 
Tables and figures          page 32 
 
4 
 
Chapter I 
Systemic Sclerosis 
 
1.1 Definition 
 
Systemic sclerosis or scleroderma (SSc) is a connective tissue disease with multi-
factorial aetiology and autoimmune pathogenesis, characterized by early endothelial 
damage and progressive fibrosis, affecting the skin and internal organs (lungs, heart, 
digestive tract and kidneys) (1.2). 
Another characteristic of the disease is the vascular impairment which includes 
morphological and functional changes, that lead to Raynaud's phenomenon (RP) and 
ulcers, frequently at periungual level (3). 
SSc is classified according to the extent of skin fibrosis into two main forms: limited 
cutaneous and diffuse cutaneous involvement (2). 
The limited subtype (lcSSc) is characterized by the association of Raynaud's 
phenomenon with fibrosis of the skin limited to the hands, face, feet and forearms 
level. Although this form is only sometimes characterized by serious organ 
involvement, affected individuals run a higher risk of pulmonary hypertension (2). 
In the diffuse form (dcSSc) the clinical course is quick and cutaneous sclerosis, 
usually preceded a few months before by Raynaud's phenomenon, which rapidly 
extends to the entire body surface, including the trunk. This form is characterized by 
early organ involvement of lung, kidney, gastro-intestinal tract and myocardium (2). 
A subgroup of patients with lcSSc has the CREST syndrome (calcinosis of the skin, 
Raynaud's phenomenon, oesophageal dysfunction, sclerodactyly, and 
telangiectasia). 
Another subtype is scleroderma sine scleroderma, that as no skin involvement (2). 
 
 
1.2 Classification 
 
A new more sensitive and specific set of criteria for systemic sclerosis has been 
proposed to identify individuals with SSc for inclusion in clinical study by the 
American College of Rheumatology (ACR) and the European League Against 
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Rheumatism (EULAR). Diagnostic measures, such as anti-nuclear antibodies and 
nailfold capillaroscopy have been included in these criteria for the first time (4,5). 
The criteria are based on various parameters, which are commonly used for the 
diagnosis of scleroderma. Noteworthy is the fact that these criteria are not diagnostic 
criteria as such are not applicable to patients with scleroderma-like disorders or 
patients who do not have sclerodactyly. The revised criteria for the classification of 
the SSc are presented in Table I (5). 
 
1.3 Epidemiology 
 
SSc is a rare disease, diagnosed each year in 67 males and 265 females/100,000 
persons (6-8). It is estimated to occur in 2,3-3,0 persons/1 million (6-8). However, as 
there are numerous oligosymptomatic forms that remains undiagnosed its prevalence 
is underestimated.  
Although there is no racial prevalence, systemic sclerosis is rare in Japanese and 
Chinese populations. There is a substantial prevalence of women over me 
(female:male ratio 9:1). The dcSSc form occurs equally in both males and females, 
conversely the lcSSc form has a strong female predominance (female:male ratio 
10:1). SSc usually appears in women in the 30-40 age range and about 85% of 
cases develop in persons 20-60 years old (6,7). There is no clear family 
predisposition (the correlation between monozygotic twins is 4%) or of any external 
known agent (6,7). 
Generally, renal and pulmonary complications are responsible for the death of 
scleroderma patients (pulmonary hypertension 12%, lung fibrosis and heart disease 
9%). 
 
 
1.4 The most serious clinical manifestations 
 
SSc has complex pathogenesis. The clinical manifestations arise from three distinct 
processes: severe vascular fibro-proliferative lesions of the small arteries and 
arterioles; dysregulation of collagen and extracellular matrix production and 
deposition at the level of the skin and internal organs; alterations in both humoral and 
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cellular immunity. Clinically manifestation of SSc is localized at level of skin, vascular 
system and internal organs (2.8). 
 
Cutaneous manifestations 
Skin damage is characteristic of the disease and is absent in a small percentage of 
patients. It sometimes includes sclerosis, discoloration and calcinosis. 
Cutaneous sclerosis evolves in three stages: 1) the skin appears oedematous, 2) it is 
sclerotic and 3) it becomes atrophic. 
The deposition of compact collagen fibres at the level of the dermis precedes 
epidermal thinning and skin appendage atrophy. The T cells are retrieved and a wide 
and progressive fibrosis of the skin and subcutaneous layers develops, favouring the 
onset of additional morphological alterations in the capillaries at a nail-bed level. The 
cutaneous fibrosis is usually symmetrical and the skin involvement may be limited to 
the fingers (sclerodactyly) or involve the entire body surface. The hands undergo a 
progressive retraction, with irreversible flexion deformity (claw hands).  
A beak-shaped nose and a reduced aperture of the mouth ("facies scleroderma"), are 
typical facial features associated with SSc teleangiectases. The fibrous process also 
affects the sweat glands, reducing their secretory function. 
Skin lesions in SSc are often discoloured with hyper/hypo pigmented areas, which 
may be very extensive. Another very common finding is calcinosis, i.e. coarse 
phosphate and calcium deposits which may also ulcerate the skin surface. The 
subcutaneous calcifications are localized more frequently at a finger tip level, bone 
eminences and the ear (8). 
 
Vascular events 
Raynaud’s phenomenon (RP), ischemic ulcers and telangiectasia, are all expressions 
of the alterations in the microvascular morphology (9-11). The best method to assess 
and classify microvascular damage is nailfold videocapillaroscopy (NVC) (3-5,9-11). 
NVC is the safest, most non-invasive, less expensive, reliable and reproducible 
method allowing for the evaluation of structural changes in the peripheral 
microcirculation in SSc. NVC is able to recognise the structural damage at an early 
stage and is a useful monitoring tool  (9-11).  
7 
 
NVC is a well-established and validated technique for the identification of nailfold 
capillary changes to distinguish secondary RP from both primary RP and healthy 
subjects. It also identifies morphological patterns that are specific to various SSc 
stages (“Early”, “Active” and “Late” patterns of microvascular damage, according to 
the classification by Cutolo et al) and calculates the microangiopathy evolution score 
(MES) used to follow disease evolution (9-11).  
Recently, several studies have demonstrated that SSc microangiopathy correlates 
with disease subsets and their severity (12-25). Furthermore, some authors have 
shown cross-sectional and predictive associations between progressive 
capillaroscopic changes and the impairment of internal organ function, i.e. lung 
disease, skin fibrosis and digital ulcers (12-25). It has now become clear that SSc 
patients with a “Late” NVC pattern have an increased risk of a complex disease and 
moderate to severe skin or visceral involvement, compared to patients with an “Early” 
or “Active” NVC pattern (12,16-20).  
The diagnostic, prognostic and therapeutic implications of NVC microvessel 
morphological analysis allows for the best clinical management. Therefore, NVC 
abnormalities have been included in the parameters established by the 2013 
ACR/EULAR classification criteria, the 2001 LeRoy criteria for the classification of 
early systemic sclerosis and the 2013 VEDOSS criteria for very early diagnosis of 
SSc (4,5,26). 
 
 
Visceral manifestations 
Visceral manifestations are very frequent in SSc and mainly affect the lungs, heart, 
oesophagus, intestines and kidneys (27-38). 
Pulmonary and cardiac manifestations 
The lungs are affected in 70-80% of scleroderma patients. The pulmonary 
manifestations of systemic sclerosis include interstitial lung disease, pulmonary 
arterial hypertension (PAH), pleurisy and pleural effusion (27-31). Interstitial fibrosis 
is frequent in patients with dcSSc, where the characteristic lesion is interstitial 
fibrosis, with dyspnoea and characteristic “velcro crackles” on auscultation (8,27-31). 
Pulmonary function testing may reveal a restrictive ventilatory defect, characterized 
by a reduction in forced vital capacity, lung compliance and diffusing capacity. High-
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resolution computed tomography (HRCT) is the most sensitive diagnostic radiological 
instrument and is able to detect the disease at an early stage, even in the presence 
of a negative X-ray. A “ground-glass” appearance is a typical feature of early fibrosis. 
(28-31). 
Pulmonary hypertension (PAH) is a common finding and may be regarded as one of 
the manifestations of the widespread small vessel arteriopathy that characterizes this 
disease: it can be the consequence of an end-stage lung fibrosis and is the leading 
cause of death in SSc patients (30,31,37,38). 
The heart is involved in 40% of patients, where the damage is characterized by a 
progressive fibrosis that compromises both the functionality and conduction of the 
myocardium. This damage may lead to cardiomyopathy, which may progress to heart 
failure and myocardial electrical instability, at times triggering ventricular arrhythmia 
(32,33). 
 
The manifestations of the gastro-intestinal tract. 
Scleroderma patients had higher prevalence of upper gastro-intestinal (GI) tract 
symptoms (heartburn, nausea and vomiting, dysphagia and epigastric pain). 
This has been reported in 50-90% of patients and it is typically result of the fibrosis 
that characterizes this disease. SSc can affect numerous sites within the GI tract, and 
patients may experience substantial dysfunction in the processes of motility, 
digestion, absorption and excretion. Oesophageal dysfunction is the most common 
GI manifestation, even if patients may also have dysfunction of the stomach, small 
intestine, colon or rectum, each of which may be responsible for severe and 
distressing symptoms (8,34,35). 
The oesophagus is the frequently involved in SSc. The fibrous replacement of the 
parietal smooth muscle causes a worsening hypotonia, with marked alteration and a 
reduction in peristalsis. The first symptom is dysphagia for solid foods follow by 
liquids. Patients also report having epigastric pain, gastroesophageal reflux, 
frequently secondary to a hiatal hernia (8,34,35). 
 
The renal manifestations 
Kidney disease is also common and the most frequent is a reduction in renal function 
due to chronic disease. Whilst the most serious clinical manifestation is  scleroderma 
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renal crisis (SRC). This life-threatening complication occurs in up to 15% of dcSSc 
cases. SRC is characterized by an abrupt rise in blood pressure over days to weeks 
and a rapidly progressive renal failure if left untreated, usually within the first 5 years 
after disease onset. Apart from diffuse disease, other risk factors include the use of 
corticosteroids/cyclosporine A, or the presence of anti-RNA polymerase III 
antibodies. The spectrum of presentation ranges from normal or mildly elevated 
blood pressure to malignant hypertension, causing elevated plasma renin levels, 
elevated serum creatinine (observed in 50% of patients), proteinuria or 
microangiopathic hemolytic anemia (seen in 50% of patients). Urine sediment may 
contain mild proteinuria, a few cells or casts. Mortality can be reduced by the 
administration of angiotensin converting enzyme (ACE) inhibitors (8,36). 
 
Evolution and prognosis 
SSc has quite a variable evolution. There are forms where the cutaneous sclerosis 
remains acro-located for years without visceral involvement, whilst other forms 
involve lesions that rapidly extend to all skin areas, with frequent organ involvement. 
The disease still has periods of activity alternating with remission.  
The prognosis of SSc depends on the visceral lesions; there is roughly a 90% five-
year survival rate, which drops to 70% at 10 years. The most frequent causes of 
death are heart, kidney or lung failure, as well as right heart dysfunction (2,8,13-18).   
 
 
1.5 Treatment outline 
 
Treating and managing scleroderma remains challenging due to the heterogeneity of 
the disease manifestations and variable clinical course. In 2009, the EULAR 
Scleroderma Trials and Research group (EUSTAR) published recommendations for 
the treatment of SSc, which was updated in 2017 (39,40) (Table II and Figure 1). 
However, to date, there is no treatment able to block disease progression, reverse 
the fibrosis or improve long-term outcome. Several studies have reported the efficacy 
of immune modulating/suppressant drugs in the treatment of this disease, although 
these have mostly been in open, uncontrolled trials and recent data support the 
benefit of immunosuppression for skin and lung fibrosis in SSc, especially when 
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administered  during the early stages of disease (39-41). The most commonly used 
immunosuppressant drugs for SSc management are: methotrexate, mycophenolate 
mofetil, azathioprine, cyclosporine and cyclophosphamide (39-41). Interestingly, an 
observational study on the efficacy of five different treatment protocols in early dcSSc  
did not observe any significant difference in outcomes (42). Summarizing: 
cyclophosphamide is recommended for skin disease in dcSSc and lung fibrosis, 
methotrexate can be used in skin disease or in patients with features of overlap 
inflammatory arthritis,  mycophenolate mofetil is being increasingly used for skin and 
lung disease and azathioprine may be an alternative option (39,40). As 
aforementioned, the choice of immunosuppressant is dictated by the organ 
complications. 
It is important to consider not only immunosuppression but also symptomatic 
treatment of symptoms. One of most important symptoms is Raynaud’s 
phenomenon, where treatment/management includes lifestyle changes, such as 
stopping smoking, avoiding cold environments, wearing layers of warm clothing and 
gloves. Moreover, calcium channel blockers, angiotensin II receptor blockers and 
selective serotonin reuptake inhibitors may be helpful. Iloprost IV, phosphodiesterase 
5 (PDE5) inhibitors and endothelin receptor antagonists (ERA) should be taken into 
consideration for severe Raynaud’s phenomenon, especially if associated with digital 
ulceration and/or critical digital ischemia. Sympathectomy may even be considered in 
severe cases (39-42).  
Gastrointestinal symptoms are extremely common and most patients have some 
element of gastroesophageal reflux, which can be treated with proton pump 
inhibitors. Many patients have severe symptoms that require higher doses to control 
symptoms or the addition of histamine 2 receptor antagonists. Prokinetics may be 
prescribed for dysphagia and rotating antibiotic courses of for small bowel overgrowth 
to avoid diarrhea (39,40) (Table I, Figure 1).  
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Chapter II 
Evaluation of skin damage by the modified Rodnan skin score and skin high 
frequency ultrasound 
 
2.1 Introduction 
 
Skin involvement is a hallmark of systemic sclerosis (SSc), its classification and 
activity (43-47). Skin damage is related to an excessive dermal deposition of 
collagenous and non-collagenous extracellular matrix components due to an altered 
production and remodeling of tissue fibroblasts and myofibroblasts (48-52).  
There are 3 stages of scleroderma skin impairment in SSc, i.e. edematous, fibrotic or 
atrophic. In the edematous phase, there is painless pitting edema of the hands and 
fingers, which may also affect the feet, legs and the forearms. This situation usually 
evolves quickly in fibrosis, with a reduction in skin elasticity. The second phase, 
which may last for many years, is characterized by hard, shiny and taut skin that is 
adherent to the sub-cutis. In the atrophic phase the skin becomes thin and is bound 
to the underlying tissue (43-48).  
Quantifying skin impairment is a must not only to assess disease activity, but also the 
severity and therapy response (53). Indeed, skin damage is a vital element as the 
severity of skin involvement inversely correlates with both survival and prognosis (44-
47). 
 
 
2.2 The modified Rodnan skin score 
 
Skin manifestation can be identified and studied by the modified Rodnan skin score 
(mRss), the validated method to evaluate the severity of skin involvement in SSc and 
to distinguish, as aforementioned, patients with either limited (lcSSc) from diffuse 
(dcSSc) cutaneous skin involvement (4,43-47). In fact, the skin damage is confined to 
the extremities (hands, forearms, feet, legs and face) in lcSSc, whilst it is present on 
the arms, chest, abdomen and thighs in dcSSc patients (4,43-47).  
The original Rodnan skin score (RSS) was developed in 1979 by Rodnan et al (54) 
and the mRSS is now used to evaluate skin thickness and has been applied as the 
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primary outcome measure in most clinical trials. It is a feasible, reliable, valid method 
responsive to change in multicenter clinical trials, especially in dcSSc.  
The mRss is a summation of ratings obtained from the clinical palpation of seventeen 
skin areas, i.e. zygoma, fingers, dorsum of hands, forearms, arms, chest, abdomen, 
thighs, legs and feet (55-57). The total skin score is the sum of the individual skin 
assessments in the 17 body areas, that provided a score from 0 (=normal skin 
thickness in entire body) to 51 (severe skin thickness in all 17 areas); the higher the 
score, the greater the extent and severity of the skin thickening. The mRss does have  
some drawbacks, as it is extremely dependent on the examiner’s skills, requires 
specific training and experience, cannot differentiate between skin thickness and 
tightness and it has high intra- and inter-observer variability (12% and 25 % 
respectively) and is unable to detect small but clinically relevant changes in skin 
thickness over time, mRss tends to worsen in early disease and improve in late 
disease, although the time of peak involvement still remains poorly defined (55-57). 
 
 
2.3 Skin high frequency ultrasound 
 
Recently, several studies have reported the utility of high frequency skin ultrasound 
(US) for early identification of skin involvement in SSc patients (58-61). Alexander 
and Miller were the first to use a 15 MHz US probe to assess skin thickness, 
publishing their findings in 1979 (62). 
Most investigators now use a US equipped with a 18-32 MHz probe, even if it has 
poor penetration, as a high frequency with a good resolution is necessary to obtain a 
clear visualization and to distinguish epidermis, dermis and subcutaneous fat. US 
allows not only for the determination of skin thickness but also provides a qualitative 
assessment (63-67). Several benefits are to be had by using US in the assessment 
of skin: it is a reliable and reproducible method to assess dermal thickness (intra- and 
inter-observer variability, 4% and 8% respectively) (58-61). Moreover, it provides 
early detection of skin involvement and it has been demonstrated that US values of 
dermal thickness are correlated to the clinical phase (53). Interestingly, a recent 
study has also demonstrated a correlation between dermal thickness and peripheral 
blood perfusion (60).  
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However, US also has drawbacks, for example the operator requires specific training 
in the correct use of the machine, i.e. setting, the probe positioning and hand 
pressure. In fact, it takes longer for the US to evaluate the same 17 points as the 
mRSS does, (15-20 minutes per pt. vs 5 minutes respectively). However, US images 
can be saved for future evaluation. 
The increased sensitivity of US in the early stages of skin involvement may well 
represent a valuable potential contribution to clinical assessment, especially when  
researching the pathogenesis and treatment of this disease. In conclusion, US is a 
promising technique to detect and manage skin impairment in systemic sclerosis and 
localized scleroderma, even if further studies are required before it can become a 
validated measure.  
 
 
2.4 The modified Rodnan skin score vs skin high frequency ultrasound 
  
Most authors have made a comparison between the mRSS and US, but only Ihn H. 
et al have compared US to histopathological findings (67). No correlation between 
local mRSS and US findings has been found, but some authors have demonstrated a 
correlation between global mRSS and US (63). The US offers a wider range of 
values for dermal thickness than the semi/quantitative mRSS, which has only 4 
integer values. In fact, the mRSS evaluates skin impairment, texture and fixation, 
whilst US distinguishes the different skin layers and makes a precise measurement of 
its thickness (45-47,58,59).  
A recent 2017 study also demonstrated that high frequency ultrasound is able to 
identify subclinical diffuse dermal involvement in lcSSc patients. The results of this 
study showed a higher DT in lcSSc than in healthy subjects in 4 of the 6 skin areas 
that had a normal mRSS (mRSS=0) in contrast with the criteria that classified these 
patients as lcSSc. The results of this research are in line with those of recent 
microarray gene expression studies, suggesting that clinically unaffected skin shares 
the peculiar gene signatures and pathology of clinically affected skin in SSc (69,70).  
The authors also confirmed that US identifies an earlier skin involvement than does 
the modified Rodnan skin score. In fact, another article demonstrated that US was 
able to identify the edematous phase preceding the palpable skin involvement in 
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early disease, thus helping to diagnose precocious skin involvement (61). Whereas 
few studies have evaluated the sensitivity that US has to perceive changes in DT  
(71). 
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Chapter III 
The role of circulating fibrocytes in systemic sclerosis 
 
3.1 The role of circulating fibrocytes in systemic sclerosis  
 
Progressive fibrosis is one of the most important hallmarks of systemic sclerosis 
(SSc) which is also characterized by a disorder of the autoimmune system (72,73). 
Activation of the immune response through autoantibody production, together with 
the recruitment and transition of endothelial cells and pericytes into active 
myofibroblasts, seems to play an important role in the progression of fibrosis in 
almost all organs. Therefore, although the pathogenesis of SSc remains unclear, 
myofibroblast activation is believed to be the step which follows microvascular 
damage (74,75). Myofibroblasts are characterized by a high expression of specific 
phenotype markers and profibrotic molecules, primarily α-smooth muscle actin 
(αSMA) and fibroblast-specific protein-1 (S100A4), as well as by an overproduction of 
extracellular matrix (ECM) proteins, such as fibronectin (FN) and fibrillar collagens 
(type I and III) (76-78). Various cell types, including endothelial cells, circulating 
mesenchymal cells and even fibrocytes, may differentiate into myofibroblasts (79). 
Fibrocytes are circulating progenitor cells derived from the bone marrow that express 
specific markers of both hematopoietic (CD34, CD43, CD45, LSP-1 and MHC class 
II) and stromal cells (collagen I and III), together with the chemokine receptors CCR2, 
CCR7, and CXCR4, which regulate their migration into inflammatory lesions 80-84). 
Circulating fibrocytes are recruited through CXCR4/CXCL12 interaction into injured 
tissues where they differentiate into fibroblasts/myofibroblasts, thereby regulating the 
healing process (by producing cytokines, chemokines and growth factors), secreting 
essential ECM proteins and promoting angiogenesis (85-87). Moreover, although 
fibrocytes are involved in physiological wound repair to local tissue injury, in chronic 
fibroproliferative disorders they may be the cause of an excessive deposition of ECM 
molecules (88). In vitro, fibrocytes appear to differentiate from circulating CD14+ 
monocytes into spindle-shaped, fibroblast-like cells and seem to have an antigen-
presenting capability, expressing class II major histocompatibility complex molecules 
(HLA-DP, -DQ, and -DR) and the CD11a, CD54 (ICAM-1: intracellular adhesion 
molecule-1), and CD58 adhesion molecules (80,89-91). When cultured in the 
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presence of a specific antigen, human fibrocytes induce antigen-presenting cell 
(APC)-dependent T-cell proliferation, which is significantly higher than what is 
induced by monocytes and nearly as high as the proliferation of purified dendritic 
cells (91).  
Human fibrocytes seem to have an antigen presenting capability and appear to be an 
important source of fibroblasts/myofibroblasts in the physiological and pathological 
tissue remodeling that characterizes SSc. Indeed, several recent studies have 
demonstrated that circulating fibrocytes are correlated with several aspects of fibrosis 
at the level of different internal organs in many diseases, including systemic sclerosis 
(92-97).  
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Chapter IV 
Experimental Section 
Correlations between mRSS and US and circulating fibrocytes percentage and 
gene expression in limited cutaneous scleroderma patients  
 
4.1 Introduction           
Systemic sclerosis (SSc) is a connective tissue disorder characterized by progressive 
fibrosis of skin and internal organs and microvascular abnormalities (1-7).  
Skin involvement may be classified by the modified Rodnan skin score (mRSS), the 
validated method to evaluate the severity of skin thickening in SSc. The mRSS is 
also used to distinguish patients with limited (lcSSc: skin damage is confined to the 
hands, forearms, feet, legs and face) from diffuse (in dcSSc, skin involvement is also 
present on the upper-arms, chest, abdomen and thighs) cutaneous involvement (54-
57).  
The mRSS has some drawbacks, as it is unable to identify slight alterations in skin 
thickness and has high intra- and inter-observer variability (55-57). Conversely, 
several authors have reported the utility of high frequency ultrasound (US) in the 
early identification of skin involvement in SSc patients and have also reported that 
this technique is very reliable (58-66). However, mRSS and US measure different 
skin properties. The mRSS measures skin thickness, texture and rigidity, whilst US 
makes an accurate identification of the different skin layers of skin and also 
measures the dermal thickness (DT) (55-66). 
In SSc, fibrosis is caused by the activation of fibroblasts and their transition into 
profibrotic myofibroblasts (76-83). After their phenotype transition, myofibroblasts 
acquire an increased persistent capability to synthesize and accumulate extracellular 
matrix (ECM) proteins, such as type I collagen (COL-1) and fibronectin (FN), initiating 
an altered process which leads to systemic fibrosis (76-83). Myofibroblast transition 
and ECM overproduction are known to be induced by several profibrotic mediators, 
including the transforming growth factor-β (TGFβ), endothelin-1 (ET-1), cytokines and 
chemokines, such as IL-6 and CCL18 (76-83).  
On the basis of this knowledge, blocking the fibroblast-to-myofibroblast transition, 
diminishing the profibrotic myofibroblast activity and related ECM overproduction 
might be important steps in reducing the fibrotic process, at least in SSc (76-83). 
The aims of this study were: 
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- firstly: to compare the performance of 2 high range ultrasound transducers (18 MHz 
and 22 MHz), in evaluating the subclinical DT changes in lcSSc patients and to 
confirm any correlation between US and mRSS in the evaluation of skin involvement 
in lcSSc patients. 
- secondly: to evaluate any correlations between mRSS, DT, measured by US with 
the 18 and the 22 probes and the percentage and phenotype of circulating fibrocytes 
in lcSSc patients.  
 
 
4.2 Methods 
Study population  
In the first part of the study we enrolled a total of 48 lcSSc patients (40 females and 
8 males), classified on the basis of a normal mRSS (score = 0) at the level of the 
upper-arms, thighs, thorax and abdomen. The SSc patients met the 2013 ACR/ 
EULAR criteria for SSc (5). A complete medical history was taken for all patients and 
a clinical examination performed (Table III). The control group consisted of 48 sex- 
and age-matched healthy subjects (CNT) (Table III). We obtained written informed 
consent to participate at this study.  
In the second part of the study a total of 8/48 of the lcSSc patients were selected (7 
females and 1 male) (Table IV).  
As no evident clinical SSc complications were present other than skin involvement 
and Raynaud’s phenomenon, the lcSSc patients were on vasodilators (mainly cyclic 
prostanoids) at enrollment. All instrumental examinations (i.e. pulmonary function 
testing, chest CT, echocardiography, etc.) were normal (Table IV). 
Peripheral venous blood samples were taken at time T0 in the 8 lcSSc patients  (7 
females and 1 male) that had a capillaroscopic “Active” pattern and in the 5 healthy 
subjects (CNT) (4 females and 1 male) (Table IV). 
The study was approved by the local Ethics Committee (protocol number 273-REG-
2015). 
Inclusion criteria: 
- written, signed and dated informed consent before starting the study; 
- no evident clinical SSc complications at the time of skin sampling; 
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- having ceased taking immunosuppressants and/or endothelin-1 inhibitors for at      
least three months before the study. 
Exclusion criteria: 
- severe organ involvement (respiratory, cardiac, renal or hepatic insufficiency) or a 
history of recurrent ulcers resistant to available therapies, diabetes, treatment-
resistant hypertension, arrhythmia; 
- manifestations of other autoimmune diseases (antibody positivity or clinical 
symptoms) that may lead to the suspicion that they had an overlap form; 
- ongoing immunosuppressive therapy with cyclosporine, cyclophosphamide, mofetil 
mycophenolate, methotrexate etc; 
- corticosteroid therapy; 
- ongoing therapy with endothelin-1 receptor antagonists. 
The Ethics Committee approved the study (protocol number 273-REG-2015). 
 
The Modified Rodnan skin score (mRSS) 
The mRSS was used for the SSc patients on the standard 17 skin areas (zygoma, 
fingers, dorsum of the hands, forearms, upper-arms, chest, abdomen, thighs, legs 
and feet) (54-57). The skin thickness was assessed by skin palpation and graded on 
a scale from 0 to 3, where 0 = normal, 1 = weak, 2 = intermediate and 3 = severe 
skin thickening (54-57).  
As aforementioned, only patients classified as having lcSSc were enrolled into the 
study to investigate any correlation between the mRSS and DT values (measured by 
both 18 and 22 MHz probe) in lcSSc patients and to compare these results to the 
CNT. The mRSS was equal to zero in all the healthy subjects in the CNT group. The 
same operator performed the mRSS in all subjects and was blinded to the US 
assessment.   
 
Skin high-frequency ultrasound (US) 
Two different US transducers were used in all the 17 skin areas of both patients and 
healthy subjects: an 18 MHz (MyLab 25, Esaote, Genoa, Italy) and a 22 MHz (MyLab 
One, Esaote, Genoa, Italy). The US measurements were based on two bi-
dimensional B-mode images. As reported in previews studies, an electronic calibre 
was used to measure the DT (59,60). The ultrasound values were recorded in 
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millimetres. The same operator performed the US evaluations for both groups and 
was blinded to the mRSS assessment. Both mRSS and US were performed on the 
same day in all patients. 
 
Nailfold videocapillaroscopy (NVC) 
In the first part of the study NVC was performed by an optical probe, equipped with 
a 200x contact lens, connected to image analysis software (Videocap, DS Medica, 
Milan, Italy) to classify all lcSSc patients on the correct microangiopathy pattern 
("Early", "Active", or "Late"), according to the classification by Cutolo et al (9-12). 
In the second part of the study we decided to select only patients with an “Active” 
microangiopathy pattern to obtain an intermediate microvascular damage, as those 
with a “Late” pattern are more likely to have organ damage, to avoid any bias due to 
the need for immunosuppressive therapy (9-12,17).  
The same operator performed the NVC evaluations and was blinded to the skin 
assessment.  
 
Cell culture 
Circulating fibrocytes were obtained from all lcSSc and CNT enrolled. Fibrocytes 
were isolated from peripheral blood mononuclear cells (PBMCs) and characterized 
by fluorescence-activated cell sorter analysis (FACS) at baseline (T0) and after 8 
days of culture (T8) in Dulbecco’s Modified Eagle’s Medium (DMEM, Euroclone, 
Milan, Italy) at 20% of Fetal Bovine Serum using anti-CD45, CXCR4, CD14, HLA-
DRII (Beckman Culter, CA, USA) and anti-COL-1 (Millipore, MA, USA) conjugated 
primary antibodies, in accordance with several other studies (18,19). Quantitative 
real-time polymerase chain reaction (qRT-PCR) was performed for COL-1, TGFβ1 
and the myofibroblast phenotype markers α-smooth muscle actin (αSMA) and 
fibroblast specific protein-1 (S100A4), using specific primers supplied by Primer 
Design, on T8-cultured SSc and CNT fibrocytes (97). Gene expression values were 
calculated using the comparative ∆∆Ct method and they corresponded to the 
expression level (fold increase) of the target gene in SSc fibrocytes compared to CNT 
fibrocytes (taken as the unit value by definition) (90). 
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Statistical analysis.  
The data were processed by non-parametric tests: a Mann-Whitney U test was 
performed to compare unpaired groups of variables and a Kruskal-Wallis test 
compared continuous variables with nominal variables that had more than two levels. 
The Spearman rank correlation test was used to search for any relationships 
between variables, along with linear regression tests. The Intraclass Correlation 
Coefficient (ICC) calculated the intra-operator repeatability. Any p-value <0.05 was 
considered statistically significant. The results are reported as median and 
interquartile range (IQR) (98). 
 
4.3 Results. 
In the first part of the study. 
The estimated DT values obtained by the 22 MHz transducer were statistically 
significantly higher than those of the 18 MHz transducer in all body areas in both 
lcSSc patients and the CNT group (Table V) (60). The median difference in DT 
values between the two transducer was 0.12±0.06 SD millimetres in lcSSc patients 
and 0.01±0.01 millimetres in the CNT group. 
The median DT values were significantly higher in lcSSc patients than in CNT, in all 
the six clinically unaffected skin areas when assessed with the 22 MHz transducer 
(Table V) (60). These differences were statistically significant in only 4/6 skin areas 
where the mRSS was in the normal range (=0), in agreement with the classification of 
lcSSc (the arms, chest and abdomen), when the 18 MHz probe was used. 
A positive statistically significant correlation was observed between the two 
transducers in the DT evaluation (p<0.0001, r=0.92), as well as between both probes 
and mRSS (p<0.0001 for both, r=0.50 for the 18 MHz transducer and r=0.58 for the 
22 MHz transducer) (60). The DT in the lcSSc patients increased progressively along 
with the microangiographic pattern (Early, Active and Late). There was also a positive 
correlation between the DT values and the MES scores (p<0.05). No correlation was 
observed between the DT and duration of either the SSc (p=0.70) or Raynaud’s 
phenomenon (p=0.60). No statistically significant correlation was observed between 
the DT and organ involvement (gastrointestinal tract, lung, heart, kidney, digital ulcer 
occurrence) in our lcSSc patients. 
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The time needed for the assessment of DT for all three methods was 26±3, 19±2 and 
10±2 minutes, for the 18 and 22 MHz probes and mRSS respectively (p<0.0001). 
There was a 96% intra-operator reproducibility for the 18 MHz transducer (95%CI 
0.92 to 0.98), 98% for the 22 MHz (95%CI 0.97 to 0.98) and 95% for the mRSS 
(95%CI 0.94 to 0.98).  
 
In the second part of the study. 
A positive correlation was observed in lcSSc patients between the percentage of 
circulating fibrocytes at T0 and both mRSS (p=0.04) and DT, evaluated by the two 
probes (22MHz p=0.03; 18MHz probe p=0.05). No correlations were observed 
between the T8-cultured fibrocytes and mRSS or US (the two probes) in lcSSc 
patients. Moreover, no correlation was observed in CNT at both T0 and T8, between 
the aforementioned values (mRSS vs fibrocytes; US 18 MHz probe vs. fibrocytes and 
US 22 MHz probe vs. fibrocytes) (Table VI). 
The FACS analysis showed an approximately two-fold higher percentage of fibrocyte 
at T0, characterized as CD45+COL-1+CXCR4+, in SSc patients than in CNT group 
(Table VI) (97). Furthermore, there was a higher percentage of fibrocytes in both the 
SSc and the CNT group from T0 to T8, confirmed previous results (Table VI) (97). 
T8-cultured SSc fibrocytes were characterized also by a significant increase of basal 
expression of αSMA, COL-1, S100A4 and TGFβ1, compared to T8-cultured CNT 
fibrocytes (p<0.01) (Figure 2) but there were no correlations between these data and 
the mRSS or the DT (for both probes) (p>0.05) (Table VII). A statistically significant 
correlation was observed between the mRSS and the total DT, evaluated by the two 
probes (22MHz p=0.05; 18MHz probe p=0.05) and between the two transducers in 
the measure of DT (p=0.04) (Table VII). There was no correlation between the DT-
US, mRSS and disease or Raynaud’s phenomenon duration (p>0.05). The DT 
evaluated by both probes was significantly higher in lcSSc patients than in the CNT 
group (Table VI).  
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4.4 Discussion  
The data of first part of the study demonstrate that lower frequency probes (18 vs 22 
MHz) might well lead to an underestimation of DT. Moreover, it was observed that a 
higher frequency probe, like the 22 MHz probe, is more sensitive in detecting 
subclinical involvement of the skin (63,67,99). Furthermore, the 22 MHz probe had a 
lower intra-operator variability than did the 18 MHz probe. This may be due to the fact 
that 22 MHz allows for a clearer identification of the different skin layers. The 22 MHz 
transducer was also able to reduce the time required for DT measurement over the 
18 MHz (60,68). 
Our observations confirmed, as reported in previous studies (60,68,100), that high 
frequency US, equipped with a 20-30 MHz probe, allows for a better resolution and 
visualization of derma, providing a more accurate DT determination and qualitative 
assessment of the skin (60,63,67,99,100). This is especially relevant in the thigh and 
upper-arm, where the identification of the different skin layers was more difficult with 
an 18 MHz transducer (60,100). 
Furthermore, this study confirms, as did a previous study of ours, that skin high 
frequency US is able to evaluate subclinical dermal involvement in patients with 
lcSSc (60,100). This finding is supported by genetic and pathophysiological studies 
(69,70).  
A statistically significant correlation between mRSS and US-DT values was observed 
with both transducers (68,100). The modified RSS and US different skin properties: 
i.e. the mRSS is influenced by skin thickness, texture and fixation, whose high 
frequency US measures DT more accurately (45,46,71,99).  
Noteworthy is the fact that several studies have recently demonstrated that skin high 
frequency US is a valid and reproducible technique to measure DT in patients with 
SSc and to identify early skin impairment and that it may also help to monitor therapy 
response (101). 
Skin US may be considered valuable and acceptable technique for use in clinical 
research into the pathogenesis of the disease and treatment efficacy, in as much as it 
is a non-invasive and safe approach (101). However, US evaluation necessitates 
training and is more time consuming than mRSS. Therefore, we are of the opinion 
that high frequency US is very valuable in the evaluation of small DT variations, such 
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as during clinical trials or for therapy assessment and in the early phase of disease 
with the aim of obtaining a very early diagnosis (58,61,102).  
Our study does have some limitations, such as the relatively small sample size and 
the fact that the US evaluation was performed by only one operator. Moreover, DT 
may vary according to age and pre/postmenopausal status (103), but this potential 
bias was overcome by enrolling sex and age-matched subjects. 
In conclusion, the first part of the study shows that high frequency US is able to 
detect early skin involvement in subclinical stages in lcSSc patients, thus supporting 
the hypothesis that US is an important tool for the assessment of skin involvement in 
this disease, in both clinical and research settings.  
The results of the second part of the study confirm that the percentage of 
circulating fibrocytes, characterized as CD45+COL-1+CXCR4+ cells, was higher in the 
SSc patients than in the CNT group (97). The study confirmed that SSc circulating 
fibrocytes show an increased αSMA, COL-1 and TGFβ1 gene expression of 
compared to CNT fibrocytes, suggesting they have a propensity for transition into 
profibrotic activated myofibroblasts, which are key cells involved in both tissue repair 
and fibrosis (97). Interestingly, the two patients who had an highest increase in the 
percentage of circulating fibrocytes from T0 to T8 also showed elevated levels in the 
αSMA and TGFβ1 gene expression. Furthermore, these two patients also had high 
US and mRSS values. 
This result confirms recent findings reporting that circulating fibrocytes might 
represent a further important source of activated fibroblasts/myofibroblasts and they 
might contribute to the increased presence of these cells in the tissues of SSc 
patients (89,97,104,105). Furthermore, circulating fibrocytes characterized as CD14-
CD34+CD45+CXCR4+COL-1+cells, have been reported to be involved in the ischemic 
and fibrotic processes of SSc. Indeed, it has been demonstrated that the percentage 
of these cells is directly correlated with the worsening of idiophatic pulmonary fibrosis 
and prognosis (84,106-111).  
Circulating fibrocytes derive from bone marrow progenitor cells and in response to 
different stimuli, i.e. chemokine ligand-receptor pairs, they extravasate into sites of 
tissue injury, differentiate into fibroblasts/myofibroblasts and contribute to the 
generation of ECM during fibro-proliferation (108-111). Several animal and human 
studies have investigated the role of fibrocytes in the pathogenesis of chronic 
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inflammatory and fibrotic disorders in different organs in autoimmune rheumatic 
diseases, such as rheumatoid arthritis (RA) and systemic ertematosus lupus (SLE): 
for example cardiac, pulmonary and renal fibrosis (108-111).  
Clearly, fibrocytes can be considered effector cells that exert different effects during 
the course of various autoimmune conditions (108-111). Fibrocytes are potentially 
involved in disease initiation and progression (108-111). Persistent activation of 
autoreactive T-cells in autoimmunity may drive fibrocyte differentiation, potentially 
amplifying disease severity and progression (108-111). Knowing the various factors 
that contribute to, or antagonize, fibrocyte production and effector functions will 
provide potential targets for therapeutic intervention strategies in different 
autoimmune conditions. 
The correlation observed in our study is in agreement with other studies, where 
fibrocytes are correlated with different tissue impairment in autoimmunity diseases 
and might well also confirm the pivotal role of these cells in the process of fibrosis 
(108-111). 
 
4.5 Conclusion 
However, larger multicentre studies should be carried out to confirm these 
preliminary data, as a relatively small number of subjects were enrolled from a single 
Centre. Moreover, this is a cross-sectional study, whilst a longitudinal study would be 
beneficial. Despite these drawbacks, the observation that the percentage of 
circulating fibrocytes is correlated with DT-US and mRSS does carry some weight as 
skin involvement in SSc is not only critical for the initial diagnosis but also has a 
prognostic relevance (112).  
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Table I. 2013 American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) criteria for the classification of systemic sclerosis. 
 
 
 
 
 
Criteria Sub-criteria Weight/score 
Skin thickening of the fingers of 
both hands extending proximal to 
MCP joints  
 9 
Skin thickening of the fingers  
(count the higher of the two)  
Puffy fingers  
Whole Finger, distal to MCP  
2 
4 
Fingertip lesions 
(count the higher of the two)  
Digital Tip Ulcers  
Pitting Scars  
2 
3 
Telangiectasia   2 
Abnormal nailfold capillaries   2 
Lung Involvement Pulmonary arterial hypertension (on RHC)  
and/or  
Interstitial  lung disease (on HRCT)  
2 
Raynaud’s phenomenon   3 
Scleroderma related 
antibodies  
Any of the anti-centromere, anti-
topoisomerase I (anti-ScL 70), anti-RNA 
polymerase III  
3 
 
Legend: metacarpo phalangeal joints (MCP)  right heart catheterisation (RHC), High-
resolution computed tomography (HRCT)  
 
* A total score of ≥ 9 is classified as SSc (Systemic sclerosis). 
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Table II. EULAR Scleroderma Trials and Research group (EUSTAR) published the 
recommendations for treatment of SSc (2009) and the update (2017). 
 
 
 
 
 
 2009 2017 
 
Raynaud’s 
Phenomenon 
Dihydropyridine 
Calcium channel blockers  
i.v. Prostaglandins 
 
 
Dihydropyridine  
Calcium channel blockers  
i.v. Prostaglandins  
PDE-5 Inhibitors  
Fluoxetin 
 
 
Digital Ulcers 
i.v. Prostaglandins 
Bosentan 
 
i.v. Prostaglandins  
PDE-5 Inhibitors  
Bosentan 
PAH 
Bosentan, 
Sitaxentan, 
Sildenafil, 
Epoprostenol 
 
 
ERA (Ambrisentan, Bosentan, 
Macitentan)  
sGC Stimulator Riociguat  
PDE-5-Inhibitors  
(Sildenafil, Tadalafil)  
Epoprostenol  
i.v. Prostaglandins 
 
 
Skin- and Lung 
Fibrosis 
 
Methotrexate for skin (early SSc)  
Cyclophosphamide for ILD 
 
Methotrexate for skin (early SSc)  
Cyclophosphamide for ILD  
Hematopoetic Stem Cell 
Transplantation 
 
SRC 
 
ACE Inhibitors  
No Steroids 
 
ACE Inhibitors  
No Steroids 
 
Gastro-  
Intestinal Tract 
 
PPI  
Prokinetics  
(rotating) Antibiotics 
 
PPI  
Prokinetics  
(rotating) Antibiotics 
 
 
Legend: i.v.: intravenous therapy; PDE-5 Inhibitors: phosphodiesterase type 5 
inhibitors; ERA: endothelin receptor antagonist; sGC: stimulator of soluble guanylate 
cyclase; ILD: interstitial lung disease; SRC: scleroderma renal crisis; PPI: proton 
pump inhibitor. 
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Table III. Clinical findings in systemic sclerosis (SSc) patients and healthy subjects 
(CNT). 
 
 
 
 
Age 
(year) 
RP 
duration 
(years) 
SSc 
duration 
(years) 
Treatment DT Total 
18 MHz Probe 
(millimetres) 
DT Total 
22 MHz Probe 
(millimetres) 
mRSS Total 
(score) 
CNT (#48) 
median 
[IQR] 
66.0 
[16.0] - - 
 
PPI 6 
Antihypertensive 
drugs 1 
14.2 
[1.2] 
14.9 
[0.8] - 
lcSSc (#48) 
median 
[IQR] 
67.0 
[16.3] 
8.0 
[9.4] 
4.5 
[7.5] 
Vasodilat 40 
ERA 10 
Cyclosp 7 
Mtx 5 
Aspirin 44 
PPI 38 
Antihypertensive 
drugs 10 
17.0 
[2.6] 
17.5 
[4.8] 
4.6 
[4.2] 
lcSSc vs 
CNT 
Stat. signif. 
n.s. - - - p<0.01 p<0.01 - 
Early  
(#16) 
median 
[IQR] 
64.0 
[19.4] 
4.0 
[6.0] 
1.8 
[2.1] 
Vasodilat 9 
ERA 1 
Cyclosp 1 
Mtx 0 
Aspirin 14 
PPI 9 
Antihypertensive 
drugs 2 
16.5 
[1.1] 
17.5 
[2.2] 
2 
[2.0] 
Active 
(#16) 
median 
[IQR] 
63.7 
[14.5] 
7.0 
[7.5] 
4.2 
[3.5] 
Vasodilat 15 
ERA 3 
Cyclosp 3 
Mtx 2 
Aspirin 15 
PPI 14 
Antihypertensive 
drugs 3 
17.9 
[2.0] 
21.1 
[2.8] 
 
4 
[2.0] 
Late  
(#16) 
median 
[IQR] 
65.9 
[15.7] 
11.6 
[10.6] 
7.5 
[5.2] 
Vasodilat 16 
ERA 6 
Cyclosp 3 
Mtx 3 
Aspirin 15 
PPI 15 
Antihypertensive 
drugs 5 
18.4 
[1.2] 
21.6 
[2.9] 
6 
[3.0] 
Early vs 
Late 
Stat. signif. 
n.s. <0.001 <0.001 - <0.02 <0.02 <0.01 
 
Legend: # = number; lcSSc = limited cutaneous SSc; RP = Raynaud’s phenomenon; 
DT = dermal thickness (ultrasound evaluation measurement in millimitres); mRSS = 
modified Rodnan skin score; Early, Active, Late = patterns of microangiopathy at 
nailfold videocapillaroscopy; ERA: endothelin-1 receptor inhibitors (average dosage 
125 mg twice/day; cyclosp: cyclosporine (average dosage 150 mg/day); Mtx: 
methotrexate (average dosage 7.5 mg/week); aspirin (average dosage 100 mg/day); 
PPI: proton pump inhibitors.  
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Table IV. Clinical findings in in limited cutaneous systemic sclerosis (lcSSc) and 
healthy subjects (CNT). RP = Raynaud’s phenomenon; DT = dermal thickness 
(ultrasound evaluation); mRSS = modified Rodnan skin score; DU = digital ulcer 
presence at the evaluation; GI = gastrointestinal involvement in our patients was  
represented by alteration of gastrointestinal motility evaluated by manometry; Lung  = 
lung involvement in our group of SSc was represented by mild / moderate fibrosis at 
the HRCT evaluation; Heart = cardiac involvement was rapresented by presence of 
systolic pulmonary artery pressure >40 mm Hg at echocardiography; limited 
cutaneous (lcSSc) or diffuse cutaneous (dcSSc), antinuclear antibody (ANA) 
patterns, centrom: centromeric (ACA+), early, active, late = patterns of 
microangiopathy at nailfold videocapillaroscopy; vasodilat: vasodilators; PPI: proton 
pump inhibitor. The results were reported as median and interquartile range [IQR], 
N.A. = not applicable.  
 
 
CNT (#5) 
median [IQR] 
lcSSc (#8) 
median [IQR] 
lcSSc vs CNT 
Stat. signif. 
Age 
(years) 
60.0 
[3.2] 
60.0 
[10.7] 
p>0.05 
RP duration 
(years) 
- 
15.5 
[11.7] 
N.A. 
SSc duration 
(years) 
- 
7.8 
[8.1] 
N.A. 
mRSS Total 
(score) 
- 
17.5 
[4.8] 
N.A. 
Organ involvement - 
DU1,GI 0,  
Lung 0, Heart 
0 
N.A. 
Skin  - 
lcSSc 8 
dcSSc 0 
N.A. 
ANA - 
Centrom 7 
Negative 1 
N.A. 
ENA  - 
Centromer 7 
Neg 1 
N.A. 
Capillaroscopy pattern - 
Early 0, Active 
8 
Late 0 
N:A. 
Treatments PPI 2 
Vasodilat 8, 
Aspirin 7 
PPI 7 
N.A. 
 
 
 
 
 
 
36 
 
Table V. Dermal thickness (DT) in healthy subjects (CNT) and in limited cutaneous 
systemic sclerosis (lcSSc) patients, evaluated by both 18 and 22 MHz transducers in 
the seventeen skin areas. 
 
Skin area  lcSSc CNT lcSSc vs CNT 
   
18 MHz 
Median DT 
[IQR] 
 
22 MHz 
Median DT 
[IQR] 
 
p value 
18 vs 22 
MHz 
18 MHz 
Median DT 
[IQR] 
 
22 MHz 
Median DT 
[IQR] 
 
p value 
18 vs 22 
MHz 
p value  
18 MHz 22 MHz 
Chees  0.88 
[0.16] 
0.90 
[0.17] 
<0.0001 
0.68 
[0.05] 
0.69 
[0.06] 
0.001 <0.0001 <0.0001 
3th right finger  
0.88 
[0.27] 
1.32 
[0.55] 
<0.0001 
0.69 
[0.10] 
0.7 
[0.10] 
<0.0001 <0.0001 <0.0001 
3th left finger  
0.93 
[0.21] 
1.32 
[0.60] 
<0.0001 
0.70 
[0.10] 
0.71 
[0.10] 
<0.0001 <0.0001 <0.0001 
Right hand dorsum  
0.85 
[0.23] 
0.97 
[0.33] 
<0.0001 
0.68 
[0.09] 
0.70 
[0.08] 
0.008 <0.0001 <0.0001 
Left hand dorsum  
0.85 
[0.23] 
0.97 
[0.33] 
<0.0001 
0.69 
[0.08] 
0.70 
[0.07] 
0.003 <0.0001 <0.0001 
Right  forearm  
1.00 
[0.29] 
1.10 
[0.43] 
<0.0001 
0.76 
[0.07] 
0.77 
[0.08] 
0.003 <0.0001 <0.0001 
Left forearm  
1.00 
[0.34] 
1.05 
[0.44] 
<0.0001 
0.76 
[0.07] 
0.77 
[0.09] 
0.003 <0.0001 <0.0001 
Right  upper-arm  
1.10 
[0.22] 
1.20 
[0.31] 
<0.0001 
0.85 
[0.12] 
0.86 
[0.12] 
0.008 <0.0001 <0.0001 
Left  upper-arm  
1.10 
[0.20] 
1.15 
[0.30] 
<0.0001 
0.85 
[0.10] 
0.86 
[0.12] 
0.005 <0.0001 <0.0001 
Chest  
1.30 
[0.30] 
1.31 
[0.20] 
<0.0001 
1.12 
[0.02] 
1.13 
[0.09] 
0.001 0.005 <0.0001 
Abdomen  
1.30 
[0.20] 
1.40 
[0.30] 
<0.0001 
1.12 
[0.02] 
1.13 
[0.05] 
0.009 0.005 <0.0001 
Right thigh  
1.30 
[0.41] 
1.40 
[0.30] 
<0.0001 
1.07 
[0.34] 
1.10 
[0.34] 
0.003 0.1 0.005 
Left thigh  
1.20 
[0.40] 
1.40 
[0.35] 
<0.0001 
1.09 
[0.34] 
1.10 
[0.34] 
0.006 0.1 0.005 
Right leg  
1.00 
[0.26] 
1.10 
[0.29] 
<0.0001 
0.93 
[0.03] 
0.94 
[0.04] 
0.004 0.01 0.005 
Left leg  
1.09 
[0.29] 
1.10 
[0.36] 
<0.0001 
0.93 
[0.03] 
0.89 
[0.04] 
0.005 0.01 0.004 
Right foot  
0.98 
[0.11] 
0.99 
[0.80] 
<0.0001 
0.86 
[0.03] 
0.89 
[0.04] 
0.009 <0.0001 <0.0001 
Left foot  
0.98 
[0.20] 
0.99 
[0.22] 
<0.0001 
0.89 
[0.04] 
0.90 
[0.04] 
0.004 <0.0001 <0.0001 
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Table VI. The percentage of fibrocytes at basal time (T0) and after 8 days of culture 
(T8), and gene expression values of -smooth muscle actin (SMA), type I collagen 
(COL 1), transforming growth factor-1 (TGF1), and fibroblast specific protein-1 
(S100A4) at T8 in limited cutaneous systemic sclerosis (lcSSc) patients and healthy 
subjects (CNT). 
 
 
 
 
 
CNT (#5) 
median [IQR] 
lcSSc (#8) 
median [IQR] 
lcSSc vs CNT 
Stat. signif. 
DT Total 18 MHz Probe 
(millimetres) 
13.5 
[1.6] 
19.5 
[4.1] 
p<0.01 
DT Total 22 MHz Probe 
(millimetres) 
14.1 
[1.3] 
18.6 
[2.7] 
p<0.01 
Fibrocytes at T0 
(%) 
0.4 
[1.2] 
0.8 
[2.7] 
p>0.05 
Fibrocytes at T8 
(%) 
60.2 
[44.6] 
56.7 
[40.7] 
p>0.05 
αSMA expression level (T8) 
1 11.1 
[6.8] 
p<0.01 
COL 1 expression level (T8) 
1 22.9 
[18.1] 
p<0.01 
TGFβ1 expression level (T8) 
1 3.6 
[3.5] 
p<0.01 
S100A4 expression level 
(T8) 
1 2.5 
[1.3] 
p<0.01 
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Table VII. Correlation between the different methods (modified Rodnan skin score, high 
frequency skin ultrasound with the 18 and 22 MHz probes) to evaluate dermal tickness (DT) 
and the percentage of fibrocytes at basal time (T0) and after 8 days of culture (T8), as well 
as gene expression values of -smooth muscle actin (SMA), type I collagen (COL 1), 
transforming growth factor-1 (TGF1), and fibroblast specific protein-1 (S100A4) at T8 in 
limited cutaneous systemic sclerosis (lcSSc) patients.  
 
 
 
 
mRSS Total 
(score) 
DT Total  
18 MHz Probe 
(millimetres) 
DT Total  
22 MHz Probe 
(millimetres) 
mRSS Total 
(score) 
- 
p=0.05 
[r=0.59] 
p=0.05 
[r=0.43] 
DT Total 18 MHz Probe 
(millimetres) 
p=0.05 
[r=0.59] 
- p=0.04  
[r=0.60] 
DT Total 22 MHz Probe 
(millimetres) 
p=0.05 
[r=0.43] 
p=0.04  
[r=0.60] 
- 
Fibrocytes at T0 
(%) 
p=0.04 
[r=0.96] 
p=0.05 
[r=0.52] 
p=0.03 
[r=0.66] 
Fibrocytes at T8 
(%) 
p=0.9  
[r=0.63] 
p=0.19 
[r=0.46] 
p=0.92 
[r=0.20] 
αSMA expression level (T8) 
p=0.22 
[r=0.48] 
p=0.48 
[r=0.30] 
p=0.67 
[r=0.16] 
COL 1 expression level (T8) 
p=0.18 
[r=0.41] 
p=0.84 
[r=0.29] 
p=0.18 
[r=44.6] 
TGFβ1 expression level (T8) 
p=0.48 
[r=0.49] 
p=0.94 
[r=0.30] 
p=0.92 
[r=0.71] 
S100A4 expression level (T8) 
p=0.49 
[r=0.63] 
p=0.18 
[r=0.45] 
p=0.26 
[r=0.22] 
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Figure 1. Update of 2017 EULAR recommendations for the treatment of systemic sclerosis. 
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Figure 2. Evaluation by quantitative real-time polymerase chain reaction (qRT-PCR) 
of the gene expression of -smooth muscle actin (-SMA), fibroblast specific 
protein-1 (S100A4), type I collagen (COL-1) and transforming growth factor-1 
(TGF1) in cultred human fibrocytes isolated from healthy subjects (CNT) and 
systemic sclerosis patients (SSc) maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) growth medium at 20% of Fetal Bovine Serum (FBS) for 8 days (T8). The 
gene expression of -SMA, S100A4, COL-1 and TGF1 in cultured human SSc 
fibrocytes was compared to that detected in cultured CNT fibrocytes, which was 
taken as unit value by definition.   
 
 
 
 
 
 
 
 
 
 
